Laser Targeted Photo-occlusion of Rat Choroidal Neovascularization Without Collateral Damage†¶
Authors:
- Ran ZeimerRZRan Zeimer
- Morton F. GoldbergMGMorton F. Goldberg
- Salvatore A. D'AnnaSDSalvatore A. D'Anna
- Stanley A. VinoresSVStanley A. Vinores
- Rhonda GrebeRGRhonda Grebe
- 1 January 2002
- journal article
- research article
- Published by Wiley in Photochemistry and Photobiology
- Vol. 75 (2) , 149-58
Abstract
Laser targeted photo-occlusion (LTO) is a novel method being developed to treat choroidal neovascular membranes (CNV) in age-related and other macular degenerations. A photosensitive agent, encapsulated in heat-sensitive liposomes, is administered intravenously. A low power laser warms the targeted tissue and releases a bolus of photosensitizer. The photosensitizer is activated after it clears from the normal choriocapillaris but not from the CNV. Forty-five experimental CNV were induced in seven rats. Five weeks after LTO, complete occlusion was observed by laser targeted angiography (LTA) in 76% of treated CNV, and partial occlusion was found in the remaining 24%. The tissues outside the CNV but within the area treated by LTO showed no flow alteration and no dye leakage. All untreated CNV were patent on LTA at 5 weeks. Light microscopy and electron microscopy confirmed the results in treated and control lesions. Moreover, treated areas next to lesions showed normal photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaris. These results indicate that LTO may improve current photodynamic therapy by alleviating the need for repeated treatments and by avoiding the long-term risks associated with damage to the RPE and occlusion of normal choriocapillaries.Keywords
This publication has 12 references indexed in Scilit:
- Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey11The Massachusetts Eye and Ear Infirmary is an owner of a patent covering the use of verteporfin and photodynamic therapy. Should the Massachusetts Eye and Ear Infirmary receive royalties or other financial remuneration related to that patent, Drs. Miller and Gragoudas would receive a share of same in accordance with the Massachusetts Eye and Ear Infirmary’s institutional Patent Policy and Procedures, which includes royalty-sharing provisions. As faculty members of the Harvard Medical School, they also adhere to their general Faculty Policies on Integrity in Science, which govern research and conflict of interest issues.Ophthalmology, 1999
- Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular DegenerationArchives of Ophthalmology (1950), 1999
- Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered BenzoporphyrinArchives of Ophthalmology (1950), 1995
- Vascular Targeting in Photodynamic Occlusion of Subretinal VesselsOphthalmology, 1994
- Retinal and choroidal vessel closure using phthalocyanine photodynamic therapyLasers in Surgery and Medicine, 1994
- Phthalocyanine photodynamic therapy: New strategy for closure of choroidal neovascularizationLasers in Surgery and Medicine, 1994
- Photodynamic Therapy of Subretinal Neovascularization in the Monkey EyeArchives of Ophthalmology (1950), 1993
- A New Model of Experimental Choroidal Neovascularization in the RatArchives of Ophthalmology (1950), 1989
- Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potentialBiochimica et Biophysica Acta (BBA) - Biomembranes, 1985
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984